Wangjing Hospital, China Academy of Chinese Medical Sciences
Welcome,         Profile    Billing    Logout  
 17 Trials 
2 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wei, Xu Ya
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
TT01488CN02, NCT05683717: A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

Recruiting
1
37
RoW
TT-01488 Tablets
TransThera Sciences (Nanjing), Inc.
B-Cell Malignancies
10/26
10/28
Zhang, Chenhao
No trials found
Zhu, Shijie
No trials found
Dong, Tao
No trials found

Download Options